IN8BIO, INC.(INAB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
INAB Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for IN8BIO, INC. (INAB), a Healthcare sector company. INAB is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of INAB by reported 13-F value include Stonepine Capital Management, Alyeska Investment Group, L.P., FRANKLIN RESOURCES, based on the most recent SEC filings. INAB trades on the Nasdaq exchange and files with the SEC under CIK 1740279. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate INAB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IN8BIO, INC. directly from SEC EDGAR.
Net Income
Q2 2026
$-4.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
+36.1% YoYOperating Income
+36.1% YoYEPS (Diluted)
+74.0% YoYTotal Assets
+54.1% YoYOp. Cash Flow
+47.4% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-19.4M +36.1% | $-30.4M -1.4% | $-30.0M -5.2% | $-28.5M -94.6% | $-14.7M -71.2% | $-8.6M |
| Operating Income | $-19.4M +36.1% | $-30.4M -1.4% | $-30.0M -5.2% | $-28.5M -94.6% | $-14.7M -71.2% | $-8.6M |
| EPS (Diluted) | $-4.44 +74.0% | $-17.05 -1605.0% | $-1.00 +26.5% | $-1.36 +7.5% | $-1.47 | — |
| Total Assets | $32.3M +54.1% | $20.9M -37.9% | $33.7M +2.0% | $33.0M -21.8% | $42.2M +101.9% | $20.9M |
| Operating Cash Flow | $-12.7M +47.4% | $-24.1M -3.5% | $-23.3M +3.2% | $-24.1M -78.6% | $-13.5M -89.4% | $-7.1M |
Get alerted when INAB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for IN8BIO, INC. including:
Top Institutional Holders of INAB
Stonepine Capital Management, LLC
$2.3M1,624,562 shAlyeska Investment Group, L.P.
$1.3M944,319 shFRANKLIN RESOURCES INC
$1.3M914,531 sh683 Capital Management, LLC
$1.0M724,637 shVANGUARD CAPITAL MANAGEMENT LLC
$126.5K88,865 shBIOS Capital Management, LP
$114.1K80,957 shGEODE CAPITAL MANAGEMENT, LLC
$102.3K72,550 shCITADEL ADVISORS LLC
$88.9K63,055 shOPPENHEIMER & CO INC
$88.9K63,042 shVANGUARD FIDUCIARY TRUST CO
$62.0K43,570 sh
| Fund | Value | Shares |
|---|---|---|
| Stonepine Capital Management, LLC | $2.3M | 1,624,562 |
| Alyeska Investment Group, L.P. | $1.3M | 944,319 |
| FRANKLIN RESOURCES INC | $1.3M | 914,531 |
| 683 Capital Management, LLC | $1.0M | 724,637 |
| VANGUARD CAPITAL MANAGEMENT LLC | $126.5K | 88,865 |
| BIOS Capital Management, LP | $114.1K | 80,957 |
| GEODE CAPITAL MANAGEMENT, LLC | $102.3K | 72,550 |
| CITADEL ADVISORS LLC | $88.9K | 63,055 |
| OPPENHEIMER & CO INC | $88.9K | 63,042 |
| VANGUARD FIDUCIARY TRUST CO | $62.0K | 43,570 |
More Healthcare Companies
View all Healthcare →Put INAB on your watchlist
Track score changes the day IN8BIO, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is INAB a good stock to buy?
13F Pro's AI-powered analysis of IN8BIO, INC. (INAB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for INAB are available on the INAB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. INAB is classified as a small company.
Which hedge funds own INAB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling INAB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IN8BIO, INC.'s investment landscape.